文献速递胸部肿瘤

Benmelstobart联合安罗替尼对比帕博利珠单抗一线治疗PD-L1阳性晚期非小细胞肺癌(CAMPASS):盲法随机对照3期试验

Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2026-03-10

CAMPASS研究在中国79个中心随机分配531例驱动基因阴性、PD-L1阳性(TPS≥1%)的晚期NSCLC患者,比较Benmelstobart联合安罗替尼与帕博利珠单抗的疗效。

要点

  • Benmelstobart联合安罗替尼较帕博利珠单抗显著延长PD-L1阳性晚期NSCLC的PFS。
  • 联合组3级及以上治疗相关不良事件发生率为59%,高血压最常见。
  • 总生存数据尚不成熟,需更长随访。

核心结论

  • 在驱动基因阴性、PD-L1阳性的晚期NSCLC中,Benmelstobart联合安罗替尼较帕博利珠单抗显著延长PFS,且未发现意外安全信号。

研究设计与样本

  • 盲法、随机、对照3期试验,在中国79个中心进行,共随机分配531例患者(联合组354例,对照组177例),按2:1比例分组。
  • 纳入18-75岁、IIIB-IV期、驱动基因阴性、PD-L1 TPS≥1%、ECOG 0-1分的初治晚期NSCLC患者。
  • 主要终点为盲法独立评审委员会评估的PFS(RECIST 1.1),在意向治疗人群中分析。

主要发现

  • 联合组3级及以上治疗相关不良事件发生率为59%(206/352),对照组为29%(51/176);最常见为高血压(26% vs 3%)。
  • 联合组治疗相关严重不良事件发生率为25%(89例),对照组为21%(37例)。
  • 联合组治疗相关死亡5例(1%),对照组4例(2%)。

关键数值与推荐

  • PD-L1肿瘤比例评分≥1%为入组标准。
  • Benmelstobart 1200 mg静脉注射每3周一次,安罗替尼12 mg口服每日一次(第1-14天)。
  • 帕博利珠单抗200 mg静脉注射每3周一次联合安慰剂。

临床怎么用

  • 对于驱动基因阴性、PD-L1阳性的晚期NSCLC初治患者,Benmelstobart联合安罗替尼可作为潜在的一线治疗选择。
  • 需注意联合方案的不良事件管理,尤其是高血压等3级及以上不良事件的发生率较高。
  • 目前总生存数据尚未成熟,需等待更长随访结果以确定生存获益。

局限性

  • 总生存数据尚未成熟,需更长随访。
  • 研究仅在中国进行,结果外推需谨慎。
  • 治疗分配对研究者开放,可能存在偏倚风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: PD-1 and PD-L1 inhibitors have been shown to synergise with anti-angiogenic agents in non-small-cell lung cancer (NSCLC). We aimed to compare benmelstobart plus anlotinib with pembrolizumab in patients with previously untreated, driver gene-negative, PD-L1-positive, advanced NSCLC. METHODS: The blinded, randomised, controlled, phase 3 CAMPASS trial was conducted in 79 centres across China. Patients aged 18-75 years with stage IIIB-IV squamous or non-squamous NSCLC, no previous systemic treatment for advanced, recurrent or metastatic diseases, a PD-L1 tumour proportion score of 1% or greater, a life expectancy of 3 months or longer, at least one measurable lesion, and an Eastern Cooperative Oncology Group performance status of 0 or 1 were randomly assigned (2:1) to receive intravenous benmelstobart (1200 mg once on day 1) plus oral anlotinib (12 mg daily on days 1-14) or intravenous pembrolizumab (200 mg once on day 1) plus placebo every 3 weeks. Randomisation was done centrally and stratified by tumour histology, PD-L1 tumour proportion score, and brain metastases. Treatment allocation was open label for investigators and masked to patients and statisticians. The primary endpoint was progression-free survival as assessed by a blinded independent review committee per Response Evalutation Criteria in Solid Tumours version 1.1 in the intention-to-treat population (all randomly assigned patients). Safety was assessed in all randomly assigned patients who received at least dose of study drug. Results reported here are from a preplanned final analysis for progression-free survival. This ongoing study is closed to recruitment and is registered with ClinicalTrials.gov, NCT04964479. FINDINGS: Between Aug 6, 2021, and Dec 14, 2022, 531 patients were randomly assigned (354 to the benmelstobart plus anlotinib group and 177 to the pembrolizumab plus placebo group). 449 (85%) patients were male, 82 (15%) were female, and 493 (93%) were of Han ethnicity. Two patients in the benmelstobart plus anlotinib group and one patients in the pembrolizumab plus placebo group were untreated and therefore excluded from the safety population. After a median follow-up of 11·4 months (95% CI 9·4-13·1) for the benmelstobart plus anlotinib group and 10·6 months (9·0-13·0) for the pembrolizumab plus placebo group, median progression-free survival was 11·0 months (9·2-12·6) and 7·1 months (5·8-9·5), respectively (hazard ratio [HR] 0·70 [95% CI 0·54-0·90]; log-rank p=0·0057). Grade 3 or worse treatment-related adverse events occurred in 206 (59%) of 352 patients in the benmelstobart plus anlotinib group and 51 (29%) of 176 patients in the pembrolizumab plus placebo group, and the most frequent one was hypertension (90 [26%] vs five [3%]). Serious treatment-related adverse events occurred in 89 (25%) patients in the benmelstobart plus anlotinib group and 37 (21%) patients in the pembrolizumab plus placebo group, the most common of which were haemoptysis (nine [3%] vs none) and immune-mediated pulmonary diseases (eight [2%] vs five [3%]). Five (1%) treatment-related deaths occurred in the benmelstobart plus anlotinib group (two due to haemoptysis and one each due to immune-mediated pulmonary disease, disease progression, and infection pneumonia) and four (2%) occurred in the pembrolizumab plus placebo group (one each due to respiratory failure, pulmonary inflammation, disease progression, and myocardial injury). INTERPRETATION: Benmelstobart plus anlotinib showed longer progression-free survival than pembrolizumab plus placebo and no unexpected safety signals were reported, suggesting benmelstobart plus anlotinib as a potential first-line option in driver gene-negative, PD-L1-positive, advanced NSCLC. Longer term follow-up is needed to establish effects on overall survival. FUNDING: Chia Tai Tianqing Pharmaceutical Group.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Zhong H, Wang J, Yang R, et al. Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial. Lancet Oncol. 2026. PMID: 41825453. doi:10.1016/S1470-2045(26)00049-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。